Pharmaceuticals
Jin Medical International Limited Receives NASDAQ Notification Letter Regarding Noncompliance with Continued Listing Rule 5550(a)(3)
CHANGZHOU, China, Sept. 28, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("JinMed" or "the Company") (NASDAQ: ZJYL), aCayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, received a written notification letter ("t...
2023-09-29 04:30
2133
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medi...
2023-09-28 21:30
1568
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titledMethod and System of Monitoring a Diabetes Treatment Plan("Predictive A1c") has been granted in Singapore and has rec...
2023-09-28 20:28
5219
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
2023-09-28 20:00
2224
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
2023-09-28 20:00
1399
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
2023-09-28 18:09
1529
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
2023-09-28 10:07
1658
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
2023-09-28 09:46
2000
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...
2023-09-28 08:30
1979
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
2023-09-28 07:38
2093
OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.
SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- In Shanghai, China, on August, OBiO Technology, a prominent leader in the Cell and Gene Therapy (CGT) field and a Contract Development and Manufacturing Organization, proudly unveiled the official launch of its state-of-the-art GMP production facility, chr...
2023-09-27 21:00
1590
Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain, Amplifying Global Production Capabilities by 30%
"A Milestone in European Pharmaceutical Manufacturing": Besins Healthcare Debuts Pioneering Plant to Address Soaring Global Demand for Hormones and to Fortify Europe's Medical Sovereignty MONACO, Sept. 27, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive He...
2023-09-27 15:56
1647
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness,Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company's recently inaugurated production facility,...
2023-09-27 12:00
2148
'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia
* Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD) SINGAPORE, Sept. 27, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division inAsia/Pacific announced today in conjunction with World Contraception Day, the inception of its 'Bay...
2023-09-27 10:00
2273
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...
2023-09-27 08:30
1497
ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation
SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation,...
2023-09-27 00:00
1767
Latest Updates of Viva's Portfolio Companies
HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the su...
2023-09-26 21:06
1811
China Jo-Jo Drugstores Announces $2.59 Million Registered Direct Offering
HANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2023-09-26 21:00
3327
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...
2023-09-26 20:51
1521
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2023-09-26 20:30
1581
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 274 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13780
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9866
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8334
